Oral 65 High SVR Rates Among US Patients Regardless of Race or Ethnicity in HCV GT1 Patients Receiving the Label-Recommended Regimen of Ombitasvir/Paritaprevir/R+dasabuvir+/-Ribavirin: Integrated Safety and Efficacy Analysis
Author Insight from Nancy Reau, MD, Chief, Section of Hepatology, Associate Director, Solid Organ Transplantation, Rush University Medical Center
![Nancy Reau, MD](https://acgcdn.gi.org/acgblog/uploads/2015/09/Nancy_Reau_headshot-082014-150x150.jpg)
What’s new here and important for clinicians?
Traditionally baseline characteristics, especially race, have led clinicians to characterize HCV patients as likely or unlikely to achieve a cure. The all-oral combination of ombitasvir/paritaprevir/r+dasabuvir+/-ribavirin has allowed treatment efficacy to overcome these hurdles.
What do patients need to know?
All-oral therapy for HCV is highly effective. If treatment was deferred in the past due to a high risk of failure, they should re-consider treatment.
Author Contact Nancy Reau, MD, Chief, Section of Hepatology, Associate Director, Solid Organ Transplantation, Rush University Medical Center
Media Interview Requests:
To arrange an interview with any ACG experts or abstract authors please contact Jacqueline Gaulin of ACG via email jgaulin@gi.org or by phone at 301-263-9000.